Baird Revises MedTech Outlook for 2026: Upgrades Tandem, Downgrades Zimmer and ResMed
Written by Emily J. Thompson, Senior Investment Analyst
Source: SeekingAlpha
Baird's MedTech Outlook: Baird upgraded Tandem Diabetes (TNDM) while downgrading Zimmer Biomet Holdings (ZBH) and ResMed (RMD), anticipating a potential rebound in the MedTech sector in the second half of 2026 if certain economic conditions improve.
Analyst Insights: Analysts highlighted ongoing challenges such as tariff headwinds and uncertainties surrounding Obamacare and Medicaid, which have contributed to five consecutive years of underperformance for MedTech compared to the S&P 500.
Stock Performance Predictions: The analysts expect that stock selection will be crucial for gains in MedTech, with Tandem's favorable market position leading to an upgrade, while Zimmer's struggles and ResMed's competitive pressures prompted downgrades.
Favorite Stocks for 2026: Heading into 2026, Baird identified Insulet (PODD), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG), iRhythm Technologies (IRTM), and Merit Medical Systems (MMSI) as preferred investment options in the MedTech space.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like TNDM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 26.33 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 19.110
Low
14.00
Averages
26.33
High
55.00
Current: 19.110
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing misleading business information, indicating significant deficiencies in the company's transparency.
- Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting serious market concerns over the company's governance and product safety.
- Class Action Preparation: The firm is preparing a class action for affected investors, allowing them to seek compensation without upfront costs, highlighting the legal risks the company faces and potential impacts on its future financial performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling similar cases, which may provide robust legal support for investors.
Continue Reading
Rosen Law Firm Investigates Tandem Diabetes Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ:TNDM) for possibly issuing misleading business information, emphasizing its commitment to protecting investor rights.
- Significant Stock Drop: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating market concerns over the company's transparency.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, demonstrating its strong commitment to investor rights and attracting affected investors with a no upfront fee structure.
- Firm's Reputation: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its leadership in the industry and robust support for investors.
Continue Reading